On March 23, 2026, the Drug Administration of Vietnam (Ministry of Health) issued an urgent dispatch to local regulatory authorities, healthcare facilities, and pharmaceutical enterprises regarding proactive drug stockpiling. This move aims to mitigate risks from escalating conflicts in the Middle East, which threaten to disrupt global supply chains and international logistics.
Key strategic measures implemented:
-
Inventory review and capacity assessment: Medical units are required to immediately audit current stocks of medicines and raw materials, while evaluating supplier delivery capabilities to establish long-term reserve plans.
-
Prioritizing essential categories: Stockpiling efforts are focused on critical drugs for emergency care and inpatient treatment, ensuring no localized shortages occur within hospitals.
-
Proactive production and import strategies: Pharmaceutical companies must develop response scenarios for market fluctuations, securing raw material inputs against international trade risks.
-
Rapid reporting mechanism: Provincial Health Departments are responsible for closely monitoring local supply conditions. Any risk of shortage must be promptly reported to the Ministry of Health for potential redistribution or urgent import authorization of unregistered drugs in pressing situations.
This directive underscores the regulatory body’s commitment to staying ahead of the curve in protecting national pharmaceutical security from negative external impacts.